About
CytoAgents, Inc develops oral immunomodulatory therapies, including CTO1681, a prostacyclin/prostaglandin analogue designed to selectively modulate cytokine signaling and inflammation for treating inflammatory diseases, oncology-related cytokine release syndrome, and other immune-driven conditions.
Explore CytoAgents, Inc's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.